Ignite Creation Date:
2024-05-06 @ 2:09 AM
Last Modification Date:
2024-10-26 @ 11:14 AM
Study NCT ID:
NCT01983501
Status:
COMPLETED
Last Update Posted:
2020-09-21
First Post:
2013-10-28
Brief Title:
A Study of Tucatinib ONT-380 Combined With Ado-trastuzumab Emtansine T-DM1 in Patients With HER2 Breast Cancer
Sponsor:
Seagen Inc
Organization:
Seagen Inc
Organization Data
Organization:
Seagen Inc
Class:
INDUSTRY
Study ID:
ONT-380-004
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Seagen Inc
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None